Secondary prevention of atherothrombotic events post-ACS in patients without AF (i.e. no OAC indication)
| Standard dose | Comments/dose reduction | |
|---|---|---|
| Rivaroxaban115 | 2.5 mg BID | In addition to aspirin ± P2Y12 inhibitor |
BID, twice daily.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.